CLINICAL TRIAL SUMMARY

MDACC Study No:2013-0185 (clinicaltrials.gov NCT No: NCT01781572)
Title:A Phase Ib/II, multicenter, open label, study of LEE011 in combination with
MEK162 in adult patients with NRAS mutant melanoma
Principal Investigator:Kevin B. Kim
Treatment Agent: None; LEE011; MEK162
Study Status:Open
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of LEE011 that can be given with MEK162.

Hide details for General InformationGeneral Information

Disease Group:Melanoma
Phase of Study:Phase I/Phase II
Treatment Agents: None
LEE011
MEK162
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Novartis
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Kevin B. Kim
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-792-2921
For General Questions about Clinical Trials:1-877-MDA-6789


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults